Fig. 2. Laboratory assessment outcomes for all patients who received onasemnogene abeparvovec over the 3-month study period, with assessments taken at baseline (T0), every 7 days for 1 month, then every 15 days for 2 months.

Levels of platelet counts (A), alanine aminotransferase (B), aspartate aminotransferase (C), and troponin I (D) are shown. Each patient is shown using a different line color, which corresponds across all four panels.